Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 1,399 shares, a growth of 329.1% from the April 30th total of 326 shares. Based on an average daily trading volume, of 1,818 shares, the short-interest ratio is currently 0.8 days.
Clinuvel Pharmaceuticals Price Performance
Shares of OTCMKTS CLVLY opened at $6.68 on Friday. Clinuvel Pharmaceuticals has a twelve month low of $5.98 and a twelve month high of $9.00. The firm has a fifty day simple moving average of $6.68 and a 200 day simple moving average of $7.45.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
